del-brax - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout

Santos (ASX: STO) warns Australia’s 20% gas reservation rule could undermine GLNG economics

Russian missiles strike Kyiv as attacks injure 17 in Zaporizhzhia and Kharkiv

Regis Resources (ASX: RRL) drops Vault Minerals bid, letting Genesis Minerals’s A$5.6bn offer proceed

Representative image of rare muscle disease research as Novartis AG’s del-brax data strengthens its Avidity Biosciences acquisition story, RNA therapy strategy, and facioscapulohumeral muscular dystrophy pipeline.

Read More

Pharma Industry News

Why Novartis’ $12bn Avidity bet suddenly looks more interesting after new del-brax data

Find out how Novartis AG’s del-brax data could strengthen its $12bn Avidity Biosciences bet and rare muscle disease strategy.

byPallavi Madhiraju

June 12, 2026

web analytics